PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ceftibuten
Drug: CTB-AVP in Tablet
Drug: Avibactam prodrug

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-21

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT06593054

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.

Recruiting

Conditions: Dwarfism, Pituitary

Interventions: Drug: Somatrogon

First Posted Date: 2024-09-19

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT06587035

Locations: 🇮🇳
Apollo Children's Hospital, Chennai, Tamil NADU, India
🇮🇳
G Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil NADU, India
🇮🇳
Apollo Speciality Hospital, Madurai, Tamil NADU, India

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: PF-07817883

First Posted Date: 2024-09-19

Last Posted Date: 2025-02-19

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT06586216

Locations: 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Genesis Clinical Research, LLC, Tampa, Florida, United States

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

Not yet recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab

First Posted Date: 2024-09-03

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 150

Registration Number: NCT06581848

Locations: 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Phase 1

Active, not recruiting

Conditions: Non Small Cell Lung Cancer
Bladder Cancer
Renal Cell Carcinoma
Head and Neck Cancer
Melanoma
Colorectal Cancer

Interventions: Biological: PF-07921585
Biological: Sasanlimab

First Posted Date: 2024-08-30

Last Posted Date: 2025-04-20

Lead Sponsor: Pfizer

Target Recruit Count: 4

Registration Number: NCT06580938

Locations: 🇺🇸
Presbyterian/St. Lukes Medical Center, Denver, Colorado, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States

and more 3 locations

A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Danuglipron

First Posted Date: 2024-08-23

Last Posted Date: 2025-01-20

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT06568731

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: Danuglipron
Drug: Atorvastatin
Drug: Rosuvastatin

First Posted Date: 2024-08-22

Last Posted Date: 2025-05-25

Lead Sponsor: Pfizer

Target Recruit Count: 82

Registration Number: NCT06567327

Locations: 🇺🇸
Qps - Mra, Llc., South Miami, Florida, United States
🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Phase 1

Recruiting

Conditions: Healthy Participants
Atopic Dermatitis

Interventions: Other: Placebo
Drug: PF-07832837

First Posted Date: 2024-08-21

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 143

Registration Number: NCT06564389

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Phase 3

Recruiting

Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Interventions: Drug: PF-06821497
Drug: Docetaxel
Drug: Enzalutamide

First Posted Date: 2024-08-13

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT06551324

Locations: 🇺🇸
Urology Centers of Alabama, Homewood, Alabama, United States
🇺🇸
Arizona Urology Specialists- Provide ICF for Review Only, Tucson, Arizona, United States
🇺🇸
Arizona Urology Specialists (AUS)-Orange Grove, Tucson, Arizona, United States

and more 161 locations

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

Phase 1

Active, not recruiting

Conditions: Colorectal Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Renal Cell Carcinoma
Ovarian Carcinoma
Neoplasms
Non-small-cell Lung Cancer

Interventions: Drug: PF-07826390
Biological: sasanlimab
Other: SOC (anti-PD-1 + platinum -based chemo)

First Posted Date: 2024-08-09

Last Posted Date: 2025-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 5

Registration Number: NCT06546553

Locations: 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸
Thomas Jefferson University Honickman Center, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Bodine Center for Radiation Therapy, Philadelphia, Pennsylvania, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy